COXIBS: EVOLUTION OF A REVOLUTIONARY CLASS: EVOLVING CONCEPTS AND ISSUES SURROUNDING COX-2 INHIBITORS

Supplement 1 to Volume 69, April 2002

SUPPLEMENT EDITOR:
MARC C. HOCHBERG, MD, MPH
UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE

Preface 3
Foreword 3
M.C. HOCHBERG, MD, MPH

Development and clinical application of COX-2–selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis 5
C.O. BINGHAM III, MD

Cyclooxygenase-2–selective inhibitors: Translating pharmacology into clinical utility 13
B.N. CRONSTEIN, MD

COX-2–selective inhibitors in the treatment of arthritis 20
T.J. SCHNITZER, MD, PhD,
and M.C. HOCHBERG, MD, MPH

Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2–selective inhibitors 31
D.A. PEURA, MD

Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors 40
J.M. SCHEIMAN, MD

Current perspective on the cardiovascular effects of coxibs 47
M.A. KONSTAM, MD, and M.R. WEIR, MD

Renal effects of nonselective NSAIDS and coxibs 53
M.R. WEIR, MD

Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy 59
A.M. FENDRICK, MD

Cyclooxygenase-2–selective inhibitors in the management of acute and perioperative pain 65
W.A. KATZ, MD

Emerging options with coxib therapy 76
M.J. LEMA, MD, PhD

Editorial development by New World Health.

This supplement was supported by an educational grant from Merck & Co.

Author financial conflict-of-interest disclosures appear within the authors' respective articles.